ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.

@article{AbdelWahab2012ASXL1MP,
  title={ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.},
  author={O. Abdel-Wahab and Mazhar Adli and Lindsay M. LaFave and Jie Gao and Todd Hricik and A. Shih and Suveg Pandey and Jay P. Patel and Y. Chung and R. Koche and F. Perna and X. Zhao and Jordan E. Taylor and Christopher Y Park and M. Carroll and A. Melnick and S. Nimer and J. Jaffe and I. Aifantis and B. Bernstein and R. Levine},
  journal={Cancer cell},
  year={2012},
  volume={22 2},
  pages={
          180-93
        }
}
Recurrent somatic ASXL1 mutations occur in patients with myelodysplastic syndrome, myeloproliferative neoplasms, and acute myeloid leukemia, and are associated with adverse outcome. Despite the genetic and clinical data implicating ASXL1 mutations in myeloid malignancies, the mechanisms of transformation by ASXL1 mutations are not understood. Here, we identify that ASXL1 mutations result in loss of polycomb repressive complex 2 (PRC2)-mediated histone H3 lysine 27 (H3K27) tri-methylation… Expand
Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.
circASXL1-1 regulates BAP1 deubiquitinase activity in leukemia
EZH2 in Myeloid Malignancies
Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms
Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy
Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation
The role of ASXL1 in hematopoiesis and myeloid malignancies
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 57 REFERENCES
...
1
2
3
4
5
...